Speakers - Sachs Associates

CONTACT
Dr Arin Ghasparian
Chief Executive Officer
ADDRESS
Virometix AG
Winterthurerstrasse 190
8057 Zurich
Switzerland
TELEPHONE
+41 44 63 56117
FAX
+41 44 63 56833
EMAIL
arin.ghasparian@virometix.com
YEAR FOUNDED
2006
Virometix AG
www.virometix.com
COMPANY PROFILE
Virometix is a privately held young innovative Swiss Biotech company developing a new class of vaccines,
which should overcome limitations of current biological vaccines in terms of safety, efficacy, speed, stability and
manufacturing cost. Virometix Synthetic Virus-Like Nanoparticle (SVLP) technology platform offers the following
value propositions:
Safety. Virometix SVLP-based vaccines avoid the use of life pathogens and the safety concerns associated with
the biological manufacturing processes used for conventional vaccines.
Quality. SVLPs are based on a proprietary lipopeptide self-assembly process that leads to atomically defined
nanoparticles with a constant size and number of lipopeptide monomers per particle, which increases the
specificity and quality of the elicited immune response and assures lot-to-lot consistency.
Efficacy. SVLPs efficiently deliver antigens to antigen presenting cells for optimal B- and T-cell responses and
induce antibodies that bind with very high affinity to the native target antigen.
Convenience. SVLPs do not require sonication, refolding, extrusion or similar processes. SVLPs can be prepared
by simply dissolving freeze-dried lipopeptide monomers in a buffer suitable for injection shortly before use.
Virometix develops vaccines for infectious diseases and cancer. Two vaccines are in early preclinical
development. Virometix offers collaborative research and licensing partnerships for selected vaccines and
disease areas.
MANAGEMENT
Arin Ghasparian, CEO and co-founder
John A. Robinson, CSO and co-founder
t back :: next u
WELCOME PHARMA LICENSING GROUPS
SPEAKERS
PRESENTING COMPANIES SUPPORTING ORGANISATIONS
ORGANISERS